

## Request for Prior Authorization GRANULOCYTE COLONY STIMULATING FACTOR



Provider Help Desk 1 (844) 236-1464

(PLEASE PRINT – ACCURACY IS IMPORTANT)

**FAX Completed Form To** 1 (877) 733-3195

IA Medicaid Member ID #	Patient name	D	ООВ	
Patient address		<u>'</u>		
Provider NPI	Prescriber name	PI	hone	
Prescriber address			Fax	
Pharmacy name Address		PI	Phone	
Prescriber must complete all informa Pharmacy NPI	Pharmacy fax	omplete or form	n will be returned.	
Prior authorization is required for therapy with granulocyte colony stimulating factor agents. Payment for non-preferred granulocyte colony stimulating factor agents will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent(s). Laboratory values for complete blood and platelet count must be obtained as directed by the manufacturer's instructions. Dosage reduction and discontinuation of therapy may be required based on the manufacturer's guidelines.  Preferred  Non-Preferred  Granix  Leukine  Nivestym  Releuko  Stimufend  Zarxio				
Fylnetra	☐ Neulasta ☐ Nyvepria	Rolvedon	Udencya Ziexte	nzo
Strength	Dosage Instructions	Quan	tity Days Supply	y
Diagnosis (or indication for the product):  Prevention or treatment of febrile neutropenia in patients with malignancies who are receiving myelosuppressive anticancer therapy.  Treatment of neutropenia in patients with malignancies undergoing myeloablative chemotherapy followed by a bone marrow transplant.  Mobilization of progenitor cells into the peripheral blood stream for leukapheresis collections to be used after myeloablative chemotherapy.  Treatment of congenital, cyclic, or idiopathic neutropenia in symptomatic patients.  On current chemotherapy drug(s) that would cause severe neutropenia (specify)  Other condition specify)				
Absolute Neutrophil Count (ANC):				
Dates of routine CBC:				_
Platelet Counts:				_
Pertinent Lab data:				=
Previous therapy (include drug name, strength and exact date ranges):				
Reason for use of Non-Preferred drug requiring prior approval:				
Possible drug interactions/conflicting drug therapies:				
Attach lab results and other documentation as necessary.				
Prescriber signature (Must match prescri	iber listed above.)	Date of submiss	sion	

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.